Atle Fund Management AB Lowers Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Atle Fund Management AB lowered its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 33.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,263 shares of the company's stock after selling 39,429 shares during the quarter. Mirum Pharmaceuticals accounts for 1.6% of Atle Fund Management AB's holdings, making the stock its 21st biggest position. Atle Fund Management AB owned approximately 0.16% of Mirum Pharmaceuticals worth $3,481,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its position in Mirum Pharmaceuticals by 4,555.0% during the first quarter. GAMMA Investing LLC now owns 5,586 shares of the company's stock worth $252,000 after acquiring an additional 5,466 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Mirum Pharmaceuticals by 174.9% during the 1st quarter. SG Americas Securities LLC now owns 19,182 shares of the company's stock worth $864,000 after purchasing an additional 12,204 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Mirum Pharmaceuticals by 2.1% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 16,685 shares of the company's stock worth $752,000 after buying an additional 339 shares in the last quarter. MPM Bioimpact LLC lifted its holdings in shares of Mirum Pharmaceuticals by 19.7% during the fourth quarter. MPM Bioimpact LLC now owns 589,579 shares of the company's stock worth $24,379,000 after buying an additional 96,856 shares in the last quarter. Finally, KBC Group NV acquired a new stake in shares of Mirum Pharmaceuticals during the first quarter worth $89,000.

Analysts Set New Price Targets

Several analysts have weighed in on MIRM shares. HC Wainwright reiterated a "buy" rating and issued a $73.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday, May 19th. Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th. Evercore ISI reaffirmed an "outperform" rating on shares of Mirum Pharmaceuticals in a report on Friday, July 11th. JMP Securities lifted their price objective on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a report on Friday, May 9th. Finally, Raymond James Financial reaffirmed a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $65.50.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 564 shares of the business's stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $48.25, for a total value of $27,213.00. Following the transaction, the senior vice president directly owned 2,903 shares in the company, valued at $140,069.75. The trade was a 16.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 14.36% of the company's stock.

Mirum Pharmaceuticals Stock Down 1.5%

NASDAQ MIRM traded down $0.80 during mid-day trading on Friday, hitting $51.93. The company's stock had a trading volume of 255,993 shares, compared to its average volume of 449,209. The company's 50 day simple moving average is $48.30 and its 200 day simple moving average is $46.26. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.20 and a twelve month high of $54.78. The company has a current ratio of 3.22, a quick ratio of 3.04 and a debt-to-equity ratio of 1.32. The firm has a market capitalization of $2.57 billion, a price-to-earnings ratio of -32.25 and a beta of 0.97.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. The company had revenue of $111.59 million for the quarter, compared to analysts' expectations of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 33.63% and a negative net margin of 20.39%. Mirum Pharmaceuticals's quarterly revenue was up 61.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.54) earnings per share. Analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.